According to earlier research [27], commercial pure KPF suppresses ovarian cancer cells’ release of vascular epithelial growth factor (VEGF) angiogenesis, which, in turn, prevents the cells from proliferating indefinitely. This evidence concerns the gene VEGFA and ovarian carcinoma.